Literature DB >> 16522781

Humoral immune response to primary rubella virus infection.

Kim M Wilson1, Carlie Di Camillo, Larissa Doughty, Elizabeth M Dax.   

Abstract

An assay capable of distinguishing between the immune response generated by recent exposure to rubella virus and the immune response existing as a result of past exposure or immunization is required for the diagnosis of primary rubella virus infection, especially in pregnant women. Avidity assays, which are based on the premise that chaotropic agents can be used to selectively dissociate the low-avidity antibodies generated early in the course of infection, have become routinely used in an effort to accomplish this. We have thoroughly investigated the immunological basis of an avidity assay using a viral lysate-based assay and an enzyme-linked immunosorbent assay (ELISA) based on a peptide analogue of the putative immunodominant region of the E1 glycoprotein (E1208-239). The relative affinities of the antibodies directed against E1208-239 were measured by surface plasmon resonance and were found to correlate well with the avidity index calculated from the ELISA results. We found that the immune response generated during primary rubella virus infection consists of an initial low-affinity peak of immunoglobulin M (IgM) reactivity followed by transient peaks of low-avidity IgG3 and IgA reactivity. The predominant response is an IgG1 response which increases in concentration and affinity progressively over the course of infection. Incubation with the chaotropic agent used in the avidity assay abolished the detection of the early low-affinity peaks of IgM, IgA, and IgG3 reactivity while leaving the high-affinity IgG1 response relatively unaffected. The present study supported the premise that avidity assays based on appropriate antigens can be useful to confirm primary rubella virus infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522781      PMCID: PMC1391971          DOI: 10.1128/CVI.13.3.380-386.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  20 in total

1.  Improvement in establishing the period of rubella virus primary infection using a mild protein denaturant.

Authors:  F Condorelli; A Stivala; R Gallo; E Musumeci; M C Scatà; L Strano; M Pennisi; G Russo; A Castro; G Scalia
Journal:  J Virol Methods       Date:  1997-06       Impact factor: 2.014

2.  Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays.

Authors:  T Zhang; C A Mauracher; L A Mitchell; A J Tingle
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Changes in antibody avidity after virus infections: detection by an immunosorbent assay in which a mild protein-denaturing agent is employed.

Authors:  S Inouye; A Hasegawa; S Matsuno; S Katow
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

5.  Rubella-specific IgG1 avidity: a comparison of methods.

Authors:  H I Thomas; P Morgan-Capner
Journal:  J Virol Methods       Date:  1991 Feb-Mar       Impact factor: 2.014

6.  Persistence of specific IgM and low avidity specific IgG1 following primary rubella.

Authors:  H I Thomas; P Morgan-Capner; G Enders; S O'Shea; D Caldicott; J M Best
Journal:  J Virol Methods       Date:  1992-09       Impact factor: 2.014

7.  Rubella-specific IgG subclass avidity ELISA and its role in the differentiation between primary rubella and rubella reinfection.

Authors:  H I Thomas; P Morgan-Capner
Journal:  Epidemiol Infect       Date:  1988-12       Impact factor: 2.451

8.  Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.

Authors:  H I Thomas; S Wilson; C M O'Toole; C M Lister; A M Saeed; R P Watkins; P Morgan-Capner
Journal:  Clin Exp Immunol       Date:  1996-02       Impact factor: 4.330

9.  The absence of loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1-infected patients.

Authors:  D Chargelegue; C M Stanley; C M O'Toole; B T Colvin; M W Steward
Journal:  J Infect Dis       Date:  1995-09       Impact factor: 5.226

10.  An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain.

Authors:  J S Wolinsky; E Sukholutsky; W T Moore; A Lovett; M McCarthy; B Adame
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  22 in total

1.  Pregnant women in and around dhaka city: are their children at risk of developing congenital rubella syndrome?

Authors:  Hasan Imam; Mahmuda Yasmin; Chowdhury Rafiqul Ahsan; Jamalun Nessa
Journal:  Indian J Microbiol       Date:  2011-02-02       Impact factor: 2.461

2.  Improved method to calculate the antibody avidity index.

Authors:  C T Perciani; P S Peixoto; W O Dias; F S Kubrusly; M M Tanizaki
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter.

Authors:  Wayne Dimech; Lena Panagiotopoulos; Barbara Francis; Nicholas Laven; Joan Marler; David Dickeson; Tony Panayotou; Kim Wilson; Robyn Wootten; Elizabeth M Dax
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

4.  Investigation into low-level anti-rubella virus IgG results reported by commercial immunoassays.

Authors:  Wayne Dimech; Nilukshi Arachchi; Jingjing Cai; Terri Sahin; Kim Wilson
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

5.  Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice.

Authors:  Zhong-Hua Deng; Ye-Xia Hao; Li-Hong Yao; Zhi-Ping Xie; Han-Chun Gao; Le-Yun Xie; Li-li Zhong; Bing Zhang; You-De Cao; Zhao-Jun Duan
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

6.  Where to Now for Standardization of Anti-Rubella Virus IgG Testing.

Authors:  Wayne Dimech
Journal:  J Clin Microbiol       Date:  2016-05-11       Impact factor: 5.948

Review 7.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 8.  Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies.

Authors:  Wayne Dimech; Liliane Grangeot-Keros; Christelle Vauloup-Fellous
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

Review 9.  Rubella.

Authors:  Nathaniel Lambert; Peter Strebel; Walter Orenstein; Joseph Icenogle; Gregory A Poland
Journal:  Lancet       Date:  2015-01-08       Impact factor: 79.321

10.  Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model.

Authors:  Rama Jayaraj; David Piedrafita; Terry Spithill; Peter Smooker
Journal:  Genet Vaccines Ther       Date:  2012-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.